Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Journal of Immunology (Baltimore, Md. : 1950)|June 8, 2022
Activation-Induced Cytidine Deaminase Impacts the Primary Antibody Repertoire in Naive MiceKatherine Bao, Juan Zhang, Alexis Scherl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 9, 2025
BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaWojciech Jurczak, Michal Kwiatek, Jaroslaw Czyz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 7, 2025
Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaJennifer A Woyach, Lugui Qiu, Sebastian Grosicki, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2025
Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)Jeff P Sharman, Talha Munir, Sebastian Grosicki, et al.
Haematologica|October 4, 2024
Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trialNirav N Shah, Michael Wang, Lindsey E Roeker, et al.
The Lancet. Haematology|May 2, 2026
Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trialM Lia Palomba, Manish R Patel, Toby A Eyre, et al.
Frontiers in Immunology|September 26, 2019
Function of CSF1 and IL34 in Macrophage Homeostasis, Inflammation, and CancerWeiYu Lin, Daqi Xu, Cary D Austin, et al.
Science Signaling|June 4, 2020
The kinase IRAK4 promotes endosomal TLR and immune complex signaling in B cells and plasmacytoid dendritic cellsCesar A Corzo, Eugene Varfolomeev, A Francesca Setiadi, et al.
Pageof 2